A novel binary expression vector for production of human IL-10 in Escherichia coli and Bifidobacterium longum

Escogido, M. L. Reyes; Rodríguez, Antonio De León; Rosa, Ana

doi:10.1007/s10529-007-9376-8

Cited by 28 publications

(18 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The amyB signal peptide (Chenoll et al, 2015) was fused in frame with the a-MSH gene to facilitate the secretion of a-MSH from the cells. An oligonucleotide carrying a fusion of RBS, the amyB signal sequence and the a-MSH gene was synthesized using codon optimization for bifidobacteria (Reyes Escogido et al, 2007). To utilize the signal peptides, we designed two plasmids, pDGMSH1 and pDGMSH2, which consisted of signal peptides with different lengths, with the predicted amino acid sequences shown in Table 2.…”

Section: Vector Constructionmentioning

confidence: 99%

Oral delivery of Bifidobacterium longum expressing α-melanocyte-stimulating hormone to combat ulcerative colitis

Wei

Yang

Ding

et al. 2016

Journal of Medical Microbiology

View full text Add to dashboard Cite

a-Melanocyte-stimulating hormone (a-MSH) is a tridecapeptide derived from proopiomelanocortin that exhibits potent anti-inflammatory properties by regulating the production of inflammatory mediators. This peptide has been well established in several inflammatory models, including inflammatory bowel disease (IBD). However, its extremely short duration in vivo limits its clinical application. To address this limitation, Bifidobacterium was used here as a carrier to deliver a-MSH. We utilized a-MSH-engineered Bifidobacterium against IBD, which is closely linked to immune and intestinal microbiota dysfunction. First, we constructed a Bifidobacterium longum secreting a-MSH (B. longum-a-MSH). We then tested the recombinant a-MSH expression and determined its bioactivity in HT-29 cells. To assess its effectiveness, B. longum-a-MSH was used against an ulcerative colitis (UC) model in rats induced by dextran sulfate sodium. The data showed that a-MSH expression in B. longum-a-MSH was effective, and its biological activity was similar to the synthesized one. This UC model experiment indicated that B. longum-a-MSH successfully colonized the intestinal gut, expressed bioactive a-MSH and had a significant anti-inflammatory effect. The results demonstrate the feasibility of preventing IBD by using B. longum-a-MSH.

show abstract

Section: Vector Constructionmentioning

confidence: 99%

Oral delivery of Bifidobacterium longum expressing α-melanocyte-stimulating hormone to combat ulcerative colitis

Wei

Yang

Ding

et al. 2016

Journal of Medical Microbiology

View full text Add to dashboard Cite

show abstract

“…Another bifidobacterial expression vector system utilized the hup (histone-like protein) gene promoter and was used to express cytosine deaminase in B. longum (202), human interleukin-10 (IL-10) in B. longum (86), the Salmonella flagellin gene in B. animalis (304), and human basic fibroblast growth factor (FGF-2) in B. breve (286). The expression of cytosine deaminase in B. longum was used to treat hypoxic tumors in mice, as previous studies had indicated that bifidobacteria selectively localized only in hypoxic tumor cells, not normal cells, pointing to the tumor-targeting properties of bifidobacteria (56,165,349,350).…”

Section: Development Of Cloning and Expression Vector Systems For Bifmentioning

confidence: 99%

Genomic Insights into Bifidobacteria

Lee

O’Sullivan

2010

Microbiol Mol Biol Rev

249

197

View full text Add to dashboard Cite

SUMMARY Since the discovery in 1899 of bifidobacteria as numerically dominant microbes in the feces of breast-fed infants, there have been numerous studies addressing their role in modulating gut microflora as well as their other potential health benefits. Because of this, they are frequently incorporated into foods as probiotic cultures. An understanding of their full interactions with intestinal microbes and the host is needed to scientifically validate any health benefits they may afford. Recently, the genome sequences of nine strains representing four species of Bifidobacterium became available. A comparative genome analysis of these genomes reveals a likely efficient capacity to adapt to their habitats, with B. longum subsp. infantis exhibiting more genomic potential to utilize human milk oligosaccharides, consistent with its habitat in the infant gut. Conversely, B. longum subsp. longum exhibits a higher genomic potential for utilization of plant-derived complex carbohydrates and polyols, consistent with its habitat in an adult gut. An intriguing observation is the loss of much of this genome potential when strains are adapted to pure culture environments, as highlighted by the genomes of B. animalis subsp. lactis strains, which exhibit the least potential for a gut habitat and are believed to have evolved from the B. animalis species during adaptation to dairy fermentation environments.

show abstract

“…Nevertheless, successful use of the P BAD system in bifidobacteria suggests that at least some E. coli promoters are recognized by the transcription machinery of bifidobacteria. This is supported by the use of the T5 phage promoter for recombinant protein expression in bifidobacteria (25,42) and P hup for expression of a codonoptimized human interleukin 10 gene in both E. coli and B. longum (68).…”

Section: Inducible Promotersmentioning

confidence: 99%

“…class II bacteriocin pediocin PA-1 in B. longum MG1, and the recombinant protein was found in the supernatants of the recombinant strain and was active against Lactobacillus plantarum and Listeria monocytogenes (52). The signal peptide of the ␤-galactosidase was successfully used for secretion of human interleukin 10 by B. longum (68). A series of expression vectors carrying the B. breve Sec2 signal peptide was constructed.…”

Section: Localization Signalsmentioning

confidence: 99%

Accessing the Inaccessible: Molecular Tools for Bifidobacteria

Sun

Baur

Zhurina

et al. 2012

Appl Environ Microbiol

View full text Add to dashboard Cite

ABSTRACTBifidobacteria are an important group of the human intestinal microbiota that have been shown to exert a number of beneficial probiotic effects on the health status of their host. Due to these effects, bifidobacteria have attracted strong interest in health care and food industries for probiotic applications and several species are listed as so-called “generally recognized as safe” (GRAS) microorganisms. Moreover, recent studies have pointed out their potential as an alternative or supplementary strategy in tumor therapy or as live vaccines. In order to study the mechanisms by which these organisms exert their beneficial effects and to generate recombinant strains that can be used as drug delivery vectors or live vaccines, appropriate molecular tools are indispensable. This review provides an overview of the currently available methods and tools to generate recombinant strains of bifidobacteria. The currently used protocols for transformation of bifidobacteria, as well as replicons, selection markers, and determinants of expression, will be summarized. We will further discuss promoters, terminators, and localization signals that have been used for successful generation of expression vectors.

show abstract

A novel binary expression vector for production of human IL-10 in Escherichia coli and Bifidobacterium longum

Cited by 28 publications

References 11 publications

Oral delivery of Bifidobacterium longum expressing α-melanocyte-stimulating hormone to combat ulcerative colitis

Oral delivery of Bifidobacterium longum expressing α-melanocyte-stimulating hormone to combat ulcerative colitis

Genomic Insights into Bifidobacteria

Accessing the Inaccessible: Molecular Tools for Bifidobacteria

Contact Info

Product

Resources

About